Health Economics›Rectal cancer›Neoadjuvant therapy

Neoadjuvant therapy

Rectal cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CapeOx, Cetuximab, RT Variant #01	—	R 133 028	35d	—	—	~2	~R 135 170 indirect	—
Capecitabine, Sorafenib, RT Variant #01	—	R 15 355	35d	—	—	~1	~R 15 355 indirect	—
Capecitabine and RT Variant #01	—	R 4 922	35d	—	—	3	R 8 817 PFS proxy	1
CapIriRT Variant #01	—	R 4 177	35d	—	—	~1	~R 4 177 indirect	—
FOLFIRINOX Variant #03	—	R 3 520	14d	—	~11.7 mo	~3	~R 10 561 PFS proxy · indirect	3
FUOX and RT Variant #01	—	R 3 365	38d	—	—	1	R 3 365 PFS proxy	1
mFOLFOX6 and RT Variant #01	—	R 2 816	14d	—	—	~6	~R 16 894 indirect	—
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~2	~R 5 240 PFS proxy · indirect	20
CapeOx, Camrelizumab, SCRT Variant #01 Partial	—	R 2 620	21d	—	—	~2	~R 5 240 indirect	—
mFOLFOX6 Variant #02	—	R 2 617	14d	~8.4 mo	~12.7 mo	~8	~R 20 933 PFS proxy · indirect	15
FULV and RT Variant #04	—	R 2 014	14d	—	—	1	R 2 014 PFS proxy	2
Fluorouracil and RT Variant #01	—	R 809	42d	—	—	1	R 809 PFS proxy	2
Radiation therapy N/A - radiation	—	—	49d	—	~9.2 mo	—	—	1
No neoadjuvant therapy Partial	—	—	—	—	~19.2 mo	—	—	8

14 of 14 regimens shown